Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory M Cote

Showing results (31-40 of 92) with videos related to

Pageof 10
Sort By:
Histopathology|May 8, 2026
Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplificationCharlotte I Wang, Soma Jobbagy, Anne B Giersch, et al.
Scientific Reports|June 17, 2015
CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaYan Gao, Yong Feng, Jacson K Shen, et al.
Cancer|March 2, 2025
Adjuvant chemotherapy in localized, resectable extremity and truncal soft tissue sarcoma and survival outcomes - A systematic review and meta-analysis of randomized controlled trialsMegan H Goh, Marcos R Gonzalez, Hillary M Heiling, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2020
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomasGregory M Cote, Edwin Choy, Tianqi Chen, et al.
Cancer|July 10, 2024
A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordomaGregory M Cote, Anthony P Conley, Steven Attia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2018
Clinicopathologic characteristics of poorly differentiated chordomaAngela R Shih, Gregory M Cote, Ivan Chebib, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Cancer Research Communications|April 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaGlenn J Hanna, Gregory M Cote, Rashmi Chugh, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 3, 2026
Multimodality Cardiovascular Imaging Reveals Late Recurrence of Cardiac NeoplasmMidori N Torpoco Rivera, Hui Chong Lau, Joseph D Nguyen, et al.
Pageof 10

Showing results (31-40 of 92) with videos related to

Sort By:
Pageof 10
Histopathology|May 8, 2026
Clinicopathologic evaluation of dedifferentiated liposarcoma lacking MDM2 amplificationCharlotte I Wang, Soma Jobbagy, Anne B Giersch, et al.
Scientific Reports|June 17, 2015
CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaYan Gao, Yong Feng, Jacson K Shen, et al.
Cancer|March 2, 2025
Adjuvant chemotherapy in localized, resectable extremity and truncal soft tissue sarcoma and survival outcomes - A systematic review and meta-analysis of randomized controlled trialsMegan H Goh, Marcos R Gonzalez, Hillary M Heiling, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2020
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomasGregory M Cote, Edwin Choy, Tianqi Chen, et al.
Cancer|July 10, 2024
A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordomaGregory M Cote, Anthony P Conley, Steven Attia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2025
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional ChondrosarcomaWilliam D Tap, Gregory M Cote, Howard Burris, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|February 28, 2018
Clinicopathologic characteristics of poorly differentiated chordomaAngela R Shih, Gregory M Cote, Ivan Chebib, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Cancer Research Communications|April 25, 2025
Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic CarcinomaGlenn J Hanna, Gregory M Cote, Rashmi Chugh, et al.
Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology|July 3, 2026
Multimodality Cardiovascular Imaging Reveals Late Recurrence of Cardiac NeoplasmMidori N Torpoco Rivera, Hui Chong Lau, Joseph D Nguyen, et al.
Pageof 10